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Objective: To assess whether the application of Functional 
Electrical Stimulation improves gait kinematics and walk-
ing ability in people with multiple sclerosis who experience 
foot drop.
Design: Acute open labelled comparative observation trial.
Participants: Twelve people (3 females, 9 males, EDSS 
2–4) with relapsing remitting multiple sclerosis (47.8 years 
(standard deviation 6.6)) who were new users of functional 
electrical stimulation.
Methods: Gait kinematics were recorded using 3D gait anal-
ysis. Walking ability was assessed through the 10-m walk 
test and the 6-min walk test. All assessments were performed 
with and without the assistance of functional electrical stim-
ulation. The effect of functional electrical stimulation was 
analysed using paired t-tests.
Results: Ankle dorsiflexion at initial contact (p = 0.026), knee 
flexion at initial contact (p = 0.044) and peak knee flexion 
during swing (p = 0.011) were significantly greater whilst 
walking with Functional Electrical Stimulation. The in-
creased peak dorsiflexion in swing of nearly 4 degrees dur-
ing functional electrical stimulation assisted walking ap-
proached significance (p = 0.069). The 10-m walk time was 
significantly improved by functional electrical stimulation 
(p = 0.004) but the 6 min walk test was not.
Conclusion: The acute application of functional electrical 
stimulation resulted in an orthotic effect through a change 
in ankle and knee kinematics and increased walking speed 
over a short distance in people with multiple sclerosis who 
experience foot drop. 
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INtroDuctIoN
People with multiple sclerosis (MS) frequently experience 
weakness (1), reduced co-ordination and spasticity of the 
muscles which consequently results in reduced functional ca-
pacity (2). Foot drop, which results in gait disturbance (3), is a 
common problem in people with MS (4). Individuals with foot 
drop tend to employ gait compensation strategies such as hip-
hitching (pelvic elevation) and circumduction (hip abduction) 
(5, 6). the use of gait compensation strategies may explain that 
the energy cost of walking in people with MS is double that of 
non-MS controls as reported by olgiati et al. (7).
Falling is a major risk for people with impaired gait (8) and 
the consequences of falling are serious. this is a particular con-
cern for people with MS as steroid use is common place (9) and 
osteoporosis is a well recognised side effect of taking steroids 
(10). therefore, in addition to an increased risk of falling people 
with MS also have an increased risk of sustaining a serious injury 
from their fall (11). Fall induced injuries are documented as one 
of the most common causes of restricted activity and disability 
among older people (12). curtailment of activity as a conse-
quence of fear of falling has also been documented in people 
with MS (13). An injurious fall can render a person with MS 
sedentary for a prolonged period; during this time deconditioning 
of skeletal muscle will occur (14). on recovery from their injury 
patients are likely to experience reduced functional capacity and 
reduced independence. It is not surprising therefore that people 
with MS curtail their activity as a consequence of fear of falling 
(13). this may, in part, account for the low levels of habitual 
physical activity documented in people with MS (1). Avoiding 
a sedentary lifestyle during adulthood not only reduces the risk 
of cardiovascular disease but also substantially extends total life 
expectancy and the cardiovascular disease-free life expectancy 
for men and women (15). Without an intervention to reduce fall 
risk, people with MS are trapped in a disuse-disability cycle. one 
way of potentially reducing this risk of falling is to assist patients 
in addressing or overcoming walking impairments such as foot 
drop. In turn, this may reduce the fear of falling and potentially 
lead to increased activity levels and independence of people 
with MS. the potential to arrest the disuse-disability spiral may 
also lead to a reduced likelihood of co-morbidity development.
Although management of foot drop has conventionally been 
achieved through the prescription of an ankle foot orthosis, 
functional electrical stimulation (FES) has recently emerged 
as an alternative treatment option. 
FES involves the application of an extrinsically derived elec-
trical impulse to a peripheral nerve muscle complex to elicit a 
contraction and produce a functional movement (16). FES can 
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be used in patients with upper motor neurone pathology who 
have an intact peripheral nervous system; such as stroke (17), 
spinal cord injury, cerebral palsy (cP) (18) and MS. A common 
application of FES is the stimulation of the tibialis anterior 
muscle to produce dorsiflexion during the swing phase of the 
gait cycle. Several studies have investigated the effects of the 
application of FES in people after stroke (19, 20) however, 
research into the use of FES to aid walking ability in people 
with MS is limited (21, 22, 24).
In a study conducted by the manufacturers of a commercially 
available drop foot stimulator the regular application of FES 
was observed to increase walking speed by 16 % with a con-
current 24 % reduction in the physiological cost of walking 
for people with MS (23). Paul et al. (24) also reported that 
people with MS who are established users of FES walked 
significantly faster with the assistance of FES. Stein et al. (25) 
assessed participants before and after a 3 month period of daily 
FES use and showed that the walking ability both with and 
without FES improved over time. In the only study to date to 
have investigated the initial effects of FES in people with MS 
no detrimental effects of walking with FES were reported, 
showing that the intervention does not impede function (22). 
however, despite employing a battery of functional ambula tory 
tests to assess the 11 people with MS who had never previously 
used FES, the findings of this study only revealed a significant 
FES-assisted improvement in one test component (stairs) (22).
Although a few studies have shown that FES improves 
walking ability in people with MS, importantly, no study has 
yet quantified the orthotic effects of FES by analysing the gait 
kinematics in new users of the device. As a result we currently 
have no characterisation of the kinematic adaptations associ-
ated with improved walking performance of people with MS 
as a result of using FES.
We hypothesised that the application of FES would favour-
ably alter gait kinematics towards a more normal gait pattern in 
people with MS who are new users of the device. therefore, the 
aim of this study was to compare the kinematic characteristics 
and walking ability of people with MS who were new users of 
FES whilst walking with and without FES.
MEthoD
the study design was an acute open-labelled comparative observation 
trial. Participants were recruited through a community NhS (National 
health Service) physiotherapy service. People with a positive diagnosis 
of MS between the ages of 18 and 70 who were referred to a physio-
therapist to be assessed for FES to manage foot drop were considered 
for participation in this study. Patients who were pregnant or breast 
feeding were excluded from the study. Participants who experienced 
a relapse were withdrawn from the study as changes in functional 
capacity could not be attributed to the intervention of FES.
this study was reviewed by the NhS lothian ethics committee, research 
and development office and the Queen Margaret University research ethics 
committee; in accordance with the declaration of helsinki. All participants 
provided written informed consent before testing commenced.
People with MS who were deemed suitable by their clinician for FES 
treatment of their dropped foot were invited to take part in this study. 
Participants made a maximum of 4 visits to the university motion 
analysis laboratory before starting to habitually use FES. Visits were 
separated by at least 3 clear days but no more than 14 days.
At each visit participants underwent gait analysis assessment; two 
10-m timed walking tests (26), and a 6-min walk test (27). the motion 
analysis and 10-m walk were carried out with and without FES during 
each session which will be referred to as FES and No FES respectively. 
gait analysis was carried out by conducting the No FES trial followed 
by the FES trial. the order in which the 10-m tests were conducted was 
counterbalanced. one 6-min walk, either with or without FES, took 
place at each session; again the order of these was counterbalanced. 
Participants were able to use additional walking aids (walking sticks) 
during testing if required. however, if they commenced testing with 
a walking aid all further testing was conducted using the same aid.
Functional Electrical Stimulation
the single channel odstock Drop Foot Stimulator (oDFS III, bio-
medical Engineering and Medical Physics, Salisbury, uk) was used 
to administer FES. this stimulator has an asymmetrical biphasic volt-
age driven wave form as the default setting; however, a symmetrical 
waveform can be selected. All participants but one received FES with 
an asymmetrical biphasic wave. the stimulator of one participant was 
set up to produce a symmetrical wave form as this type of stimulation 
lifted the foot more effectively. the intensity of the current amplitude 
ranged from 20 to 70 mA and was determined by the amplitude required 
to achieve adequate foot clearance during the swing phase of the gait. 
the stimulation frequency was 40 hz. this frequency is usually used 
for FES as it provides a sustained smooth contraction without tiring 
the muscle too quickly. output time, extension time and ramp were 
adjusted if required for each subject to optimise the amount and tim-
ing of ankle dorsiflexion.
Prior to the participant’s first trial the stimulator unit was fitted 
as part of their routine care by their physiotherapist, who was quali-
fied to fit the stimulator unit. A FES device was fitted at each testing 
session using the same stimulation parameters set up by the treating 
clinician. the device was only switched on during FES assisted trials. 
one square 50 x 50 mm gel surface electrode (PAlS, Platinum blue, 
Nidd Valley Medical ltd, knaresborough ltd) was placed over the 
common peroneal nerve as it passes over the head of the fibula and 
another over the motor point of the tibialis anterior.
Gait analysis
Participants changed into tight fitting lycra shorts on arrival and height, 
weight, knee width, ankle width and leg length were measured. these 
measurements were required for the calculation of the ankle, knee and 
hip joint centres by the motion analysis software (Vicon Plug in gait). 
A lower back support was used to reduce skin movement around the 
pelvis, when required.
three dimensional gait analysis was undertaken using a 100 hz 8 
infra-red camera Vicon Nexus 3D motion analysis system (Vicon Mo-
tion Systems, oxford, uk). Participants had 14-mm2 passive reflective 
sphere makers placed on their lower limbs and the pelvis according 
to the Vicon Plug-In-gait manual which is based on the helen hays 
marker system (28). A static trial was conducted using a knee alignment 
device (KAD) to make a direct measure of the knee flexion extension 
axis. The KADs were removed and standard 14-mm reflective markers 
were attached over the lateral epicondyle of each femur for the walk-
ing trials. Walking was assessed barefoot. Participants were asked to 
walk a distance of 7 m across the lab whilst the Vicon motion analysis 
system was recording; this constituted one trial. A minimum of 8 trials 
were recorded with and without FES to ensure that 6 trials for each 
condition were viable for analysis. Unaided walking was assessed first 
to eliminate any carry over effect of FES. Participants were able to sit 
down between trials. on completion of gait analysis participants were 
sat down for 10 min before commencing further testing.
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Walking performance tests
Participants were asked to walk at their preferred walking speed (PWS) 
along a straight length of wall for 10 m in accordance with rossier & 
Wade (29). Participants were also asked to walk continuously around 
the 16.5 m elliptical course for 6 min in accordance with Enright (30).
Kinematic data processing
lower limb angles in the sagittal, transverse and frontal plane were 
derived from the 3D marker trajectories and patient measurements 
using the Plug in gait software. kinematic data was time normalised 
so that every trial included the data between two consecutive foot 
strikes which was defined as one gait cycle. The following angles 
were derived from each trial for statistical analysis: ankle dorsiflexion 
at initial contact, peak dorsiflexion in swing, knee flexion at initial 
contact and peak knee flexion in swing and sagittal hip range of motion 
(flexion minus extension). The average value of each of these angles 
was calculated over the 6 trials for each participant and each condition.
the gait Deviation Index (gDI) is a multivariate measure of overall 
gait quality (31) developed to describe the gait of children with cP. 
A score of 100 is achieved by individuals without any neurological 
problem, while a mean score of 85 has been found for children with cP 
without functional limitations in their walking (gross Motor Function 
Classification System I) while those with several mobility problems 
and using power mobility aids for longer distances (gross Motor 
Function Classification System IV) were reported to have a mean score 
of 55 (32). the gDI was computed from pelvis, hip, knee and ankle 
angles derived from 3D gait analysis; the lower the score the higher 
the deviation from the average unimpaired person.
Statistical analysis
No accommodation or learning effects were observed over the 4 testing 
sessions and all analyses were based on the mean data. comparisons 
between the FES and No FES trials were conducted on data collected 
for the most affected leg. After confirming that data was normally 
distributed according to the Shapiro-Wilks test differences between 
the No FES and FES conditions were investigated using the paired 
t-test. Significance was accepted at p < 0.05.
rESultS
the descriptive characteristics of the 12 participants recruited 
into this study are given in table I. Initial comparison of 
unaided walking revealed a significant lower peak dorsiflex-
ion during swing (p = 0.015) of the affected compared to the 
unaffected leg thus justifying the use of an assistive device to 
correct drop foot.
There was a significant increase in dorsiflexion (p = 0.026) 
and knee flexion (p = 0.044) at initial contact during FES as-
sisted walking compared to unaided walking (table II). Peak 
dorsiflexion during swing was nearly 4° degrees higher whilst 
walking with FES, but this difference did not reach statistical 
significance (p = 0.069). the application of FES resulted in an 
increased peak knee flexion during swing which was signifi-
cantly different (p = 0.011) from the No FES condition. Figs 
1 and 2 show the sagittal ankle and knee kinematics averaged 
over the 12 participants.
 There was no significant difference in hip range of motion 
(p = 0.089) nor stride length (p = 0.140) between FES and No 
FES conditions (table II). the gDI, which is a global measure 
of gait quality, was not significantly different between conditions 
however the difference approached significance (p = 0.061) with 
FES conferring a positive effect on gDI (table II).
table I. Participant characteristics
Females/males, n 3/9
Age, years, mean (SD) 47.8 (6.6)
height, m, mean (SD) 1.73 (0.06)
body mass, kg, mean (SD) 85.9 (14.8)
bMI, kg/m2, mean (SD) 28.3 (3.9)
Walking stick users, n 4
SD: standard deviation.
table II. Results of the kinematic outcome measures and p-values of 
paired t-tests between No FES and FES conditions
Mean (SD) p-value
Ankle flexion at initial contact, °
No FES –5.6 (6.5) 0.026*
FES –0.3 (4.5)
Peak dorsiflexion during swing, °
No FES –0.9 (6.9) 0.069
FES 2.9 (3.5)
Knee flexion at initial contact, °
No FES 5.4 (6.7) 0.044*
FES 7.8 (5.8)
Peak knee flexion during swing, °
No FES 38.8 (10.7) 0.011*
FES 47.7 (10.8)
Hip Range of Motion, °
No FES 31.1 (5.5) 0.089
FES 32.0 (5.8)
gait Deviation Index
No FES 79.1 (9.9) 0.061
FES 80.7 (9.5)
Stride length, m
No FES 0.92 (0.1) 0.140
FES 0.94(0.1)
*p < 0.05.
FES: functional eletric stimulation; SD: standard deviation.
Fig. 1. Ankle dorsi-plantar flexion angle over the gait cycle (initial contact 
to initial contact) averaged over the 12 participants. Error bars indicate 
the standard error. Dorsiflexion angle is positive. Functional electric 
stimulation (FES) grey line, No FES black line. healthy controls thick 
black line with ± one standard deviation in dotted line.
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the results of the walking performance tests are in shown 
table III. Participants completed the 10-m walk test sig-
nificantly quicker whilst walking with the assistance of FES 
(p = 0.004). however, there was no difference in 6 min walk 
test resultsbetween conditions (p = 0.484).
DIScuSSIoN
Initial analysis of unaided walking illustrated that participants 
in the current study were experiencing drop foot in their most 
affected leg and this thus justified the use of an assistive device 
to aid walking. 
the acute application of FES to the tibialis anterior of people 
with MS with foot drop resulted in an increased knee flexion in 
swing and increased dorsiflexion and knee flexion at initial contact. 
The significant increase in knee flexion during swing will 
have contributed to an improved foot clearance which allows 
the leg to swing through freely during the swing phase of the 
gait cycle. this demonstrates that improved ground clearance 
is achieved immediately upon application of FES. Although 
the improved peak dorsiflexion during swing with FES was not 
statistically significant, it was apparent that the application of 
FES favourably alters the kinematics of the affected leg and 
this orthotic benefit of FES has the potential to reduce the risk 
of tripping and falling.
the only other study to date to investigate the effect of FES 
on gait kinematics in people with MS reported an increase in 
ankle dorsiflexion at initial contact but concluded that all other 
parameters were variable in their response (33). this study 
was conducted on a small sample of 4 participants, however, 
the results reported were in line with that of the current study.
Peak dorsiflexion and peak knee flexion were significantly 
greater at initial contact which is arguably the most important 
phase of the gait cycle. this is the point in the gait cycle that 
the foot can catch on the ground and result in a trip or fall. the 
increased dorsiflexion and knee flexion at initial contact with 
the application of FES reduces the chance of this happening. 
therefore the phase of the gait cycle which poses the greatest 
risk of patients falling shows the greatest improvement by 
the application of FES. this could increase patients walking 
confidence and therefore increase their volume of walking 
thereby breaking the disuse disability cycle (11, 34).
Participants walked significantly faster over the 10-m during 
FES assisted walking trial which reveals that the improvements 
in gait kinematics translate into an improvement in walking 
ability over short distances. the 5% improvement in walking 
speed over the short distances, seen in the current study, was 
less compared the study by taylor et at. (23) who reported 
improvements of 16% in walking speed over 10 m in a group 
of 21 people with MS who were established users of FES. 
however, the 5% improvement in the 10-m test in our study 
agrees with the 3.9% improvement with FES in the 10-m test 
as reported by Stein at al. (25) at their first assessment. 
In the current study no improvement in walking speed 
was apparent during the 6-minute walk test. This finding is 
inconsistent with previous research which investigated the 
use of FES in people with MS (24, 25). Paul et al. (24) tested 
established users of FES and reported a significant improve-
ment in walking speed as measured by the 5-min walk test. 
however, the participants in this study were habitual users of 
FES therefore this may suggest a habituation period is neces-
sary before any improvements in functional walking ability 
can be expected. An improved orthotic effect after a 3-month 
use of FES was reported by Stein et al. (25) who found that 
the orthotic effect on the 4-min walk was improved from 2.3% 
at the first assessment to 5.7% after habitual use of FES for 3 
months in people with progressive neuro-disorders of which 
31 out of 32 had MS. Also in the study by Stein et al. (25), 
effort over the 4-min walk as measured by the Physical cost 
Index (PCI) showed no orthotic benefit of FES at the first as-
sessment but a 5.9% improvement at 3 months of habitual use.
the participants in the current study were not habitual users 
of FES and this may account for the inconsistency in the results 
of the timed distance walk. Participants were not habituated to 
the device and may not have established a new walking pattern 
which may have hindered any improvement. Also due to the 
fact that FES was new to the participants of this study they may 
have experienced fatigue of the tibialis anterior (tA) during 
the 6-min walk test. Prior to the application of FES the tA may 
table III. Results of the walking performance measures and p-values of 
paired t-tests between No FES and FES conditions
Mean (SD) n p
10-m walk, s No FES 12.7 (3.7) 11 0.004*
FES 12.1 (3.5) 11
6-min walk, m No FES 296 (47) 8 0.484
FES 289 (40) 8
FES: functional electric stimulation; SD: standard deviation.
Fig. 2. Average knee flexion-extension angle over the gait cycle (initial 
contact to initial contact).averaged over the 12 participants. Error bars 
indicate the standard error. Flexion angle is positive. Functional electric 
stimulation (FES) grey line, No FES black line. healthy controls thick 
black line with ± one standard deviation in dotted line.
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have experienced reduced neural innervation and as a result 
may have atrophied. hence these participants were having a 
supramaximal contraction applied to a deconditioned muscle. 
Everaert et al. (35) studied a subgroup of the participants in 
Stein’s study (25) establishing the neuroplastic mechanisms be-
hind the therapeutic effects, i.e. the effect of prolonged FES on 
the walking ability without FES. they found large increases in 
the maximal voluntary contraction and motor evoked potentials 
after 3 months use of FES and suggested that these increases 
may responsible for the therapeutic effect on walking speed. 
It is possible that together with the local muscle adaptations 
discussed above, strengthening of the motor cortical areas may 
be responsible for an improvement of orthotic effect over time.
the study is limited by the small sample size, and the large 
standard deviations of the outcome measures indicating a 
substantial variation among the participants in both walking 
pattern and performance. However, the study was sufficiently 
powered to detect statistically significant differences in both 
gait kinematics and walking performance between the No 
FES and FES conditions at group level. Future studies are 
required to evaluate whether the benefit of FES depends on 
patient characteristics such as type and progression of MS, 
neuromuscular properties and gait pattern.
Clinical implications
the results of this study support the use of FES to combat 
foot drop in people with MS in the clinical setting as walk-
ing ability was improved over short distances. the study also 
demonstrates that the application of FES does not hinder 
walking ability. therefore prescription of the device in the 
clinical setting will not impede patients’ ambulatory function.
In conclusion, this study illustrates that the acute application 
of FES delivers an orthotic benefit by increasing ankle dorsi-
flexion and knee flexion at initial contact and knee flexion in 
swing, thus reducing the risk of tripping and falling. Walking 
ability over short distances in people with MS with drop foot 
who are new users of the device was also improved with FES.
No beneficial effect of the acute application FES was found 
for the 6-min walking test, but as discussed above, this may be 
the lack of habituation to the device. habitual use of FES has 
been shown to increase the orthotic effects and also to thera-
peutic effects on walking ability in people with MS (25, 35). 
however, no long term studies have explained this improved 
walking ability through the analysis of the gait kinematics.
Further appropriately powered long term studies into the effects 
of prolonged use of FES on the gait kinematics of people with 
MS are required in order the explain the altered gait mechanisms, 
which result in the long-term orthotic effects in people with MS.
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